Additionally, the activation of NLRP3 can reshape the tumour immune microenvironment, recruit MDSCs, weaken the body's antitumour immunity, assist tumour cells in resisting chemotherapy, and reduce the sensitivity of tumour cells to oxaliplatin [42]. This evidence concerns the gene NLRP3 and neoplasm.